This could be a promising strategy for treating metastatic prostate cancer, especially when resistance is encountered with androgen-related therapies that target microtubules and AR nuclear translocation and poor efficacy of novel immunomodulatory approaches such as CAR-T cells and immune checkpoint inhibitors. The gene discussed is AR; the disease is prostate carcinoma.